The Food and Drug Administration approved a groundbreaking new oral drug for pancreatic patients suffering from the most aggressive form of the disease. Daraxonrasib, which targets a mutation in a gene called KRAS, doubled the survival time in patients who participated in the trial.
For more context and news coverage of the most important stories of our day, click here:
Source: NBC News